Sellas Life Sciences Stock Today
| SLS Stock | USD 1.21 0.13 12.04% |
PerformanceOK
| Odds Of DistressLow
|
Sellas Life is selling for under 1.21 as of the 20th of March 2025; that is 12.04 percent increase since the beginning of the trading day. The stock's lowest day price was 1.08. Sellas Life has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of December 2017 | Category Healthcare | Classification Health Care |
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company was founded in 2012 and is headquartered in New York, New York. The company has 78.58 M outstanding shares of which 8.65 M shares are at this time shorted by investors with about 2.9 days to cover. More on Sellas Life Sciences
Moving together with Sellas Stock
Moving against Sellas Stock
Sellas Stock Highlights
| Thematic Idea | Biotech (View all Themes) | ||||
| Old Names | [Standard Life UK Smaller Companies Trust plc, Solaris Resources Inc, JANUS CAPITAL GRP, JANUS CAPITAL GRP - Dusseldorf Stock Exchang, JANUS CAPITAL GRP - Frankfurt Stock Exchang] | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, HNX 30, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsSellas Life can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sellas Life's financial leverage. It provides some insight into what part of Sellas Life's total assets is financed by creditors.
| |||||
Sellas Life Sciences (SLS) is traded on NASDAQ Exchange in USA. It is located in Times Square Tower, New York, NY, United States, 10036 and employs 16 people. Sellas Life is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 95.08 M. Sellas Life Sciences runs under Biotechnology sector within Health Care industry. The entity has 78.58 M outstanding shares of which 8.65 M shares are at this time shorted by investors with about 2.9 days to cover.
Sellas Life Sciences has about 26.99 M in cash with (31.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sellas Life Probability Of Bankruptcy
Ownership AllocationSellas Life Sciences shows a total of 78.58 Million outstanding shares. About 91.3 % of Sellas Life outstanding shares are held by general public with 0.16 (%) owned by insiders and only 8.54 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sellas Ownership Details
Sellas Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Mariner Wealth Advisors Llc | 2024-12-31 | 50.6 K | |
| Virtu Financial Llc | 2024-12-31 | 41.2 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 16.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 15.8 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 15.7 K | |
| Jane Street Group Llc | 2024-12-31 | 12.3 K | |
| Equitable Holdings Inc | 2024-12-31 | 12.1 K | |
| Commonwealth Equity Services Inc | 2024-12-31 | 12.1 K | |
| Prosperity Financial Group, Inc. | 2024-12-31 | 11.5 K | |
| Vanguard Group Inc | 2024-12-31 | 2.3 M | |
| Anson Funds Management Lp | 2024-12-31 | 1.2 M |
Sellas Life Historical Income Statement
Sellas Stock Against Markets
Sellas Life Corporate Management
| Barbara Esq | General VP | Profile | |
| Stacy Yeung | Associate VP | Profile | |
| Jrg Breitkopf | Head Operations | Profile | |
| ScD MD | President, Founder | Profile | |
| Barbara Wood | Gen VP | Profile | |
| Andrew Elnatan | Chemistry, Affairs | Profile | |
| Robert Francomano | Senior Officer | Profile |
Additional Tools for Sellas Stock Analysis
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.